KENTON H. ZAVITZ

Kenton H. Zavitz, PhD
Director of Clinical Affairs, Cambridge Cognition Ltd

Dr. Zavitz has over 17 years of biotechnology and pharmaceutical experience with involvement in all aspects of the industry from drug discovery and clinical development through to pre-commercialization. Prior to joining Cambridge Cognition, he served as Chief Scientific Officer for New Mexico-based biotech Zocere Inc., where he worked on developing a neuroprotectant drug designed to combat brain injury resulting from stroke. He currently serves on the Scientific Advisory Board for Exonate Limited, a start-up founded in 2013 at the University of Nottingham. From 1998 to 2012, Dr. Zavitz worked at Myriad Pharmaceuticals, Inc. in Salt Lake City and served in a variety of roles, including Senior Director of Clinical Affairs, Chief Scientist of the tarenflurbil clinical development program (an investigational drug for the treatment of Alzheimer’s disease, developed through Phase 3), Director of Neurodegeneration Therapeutics Discovery and Director of Strategic In-licensing and Scientific Evaluation. Dr. Zavitz received his PhD in Biochemistry and Molecular Biology from The Sloan-Kettering Division of the Weill Cornell Graduate School of Medical Sciences in New York City. He was a Postdoctoral Fellow at the UCLA School of Medicine, and was awarded fellowships from the Leukemia Society of America and the Jane Coffin Childs Memorial Fund for Medical Research.

« Back to Agenda         View the abstract "Cognitive assessments for neuroscience drugs in early phase studies" »